Span

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Span

Quick Facts

Property Description
Active ingredient Drotaverine hydrochloride
Form Tablet and Solution for Injection
Pharmacological class Musculotropic Antispasmodic Agent
General purpose Relieves visceral spasms and cramping
Origin Synthetic pharmaceutical invention

Span is a commercially recognized pharmaceutical product containing the single active ingredient, Drotaverine (typically as the hydrochloride salt). It is primarily categorized as a musculotropic antispasmodic agent, and its fundamental purpose is to relieve painful, involuntary tightening of internal organs, known as visceral spasms, by acting directly on the affected muscle tissue.

What Type of Medication is Span (Drotaverine)?

Drotaverine is a substance classified under the World Health Organization (WHO) Anatomical Therapeutic Chemical (ATC) system category A03AD02 (Papaverine and derivatives, Drotaverine). It is utilized in managing smooth muscle spasms. As a benzylisoquinoline derivative, Drotaverine is a laboratory-synthesized small molecule drug, not a naturally derived compound. Its distinct advantage lies in its mechanism, which involves acting directly on the muscle fiber itself, making its relaxation action independent of the body's nerve signals. This specialized approach provides direct relief during episodes of muscle cramping, such as those that might occur in the gastrointestinal or urinary tracts.

Composition, Forms, and General Purpose

The medication is formulated around the core substance Drotaverine hydrochloride and is manufactured in two main pharmaceutical preparations: an oral tablet and a sterile solution for injection suitable for parenteral administration. The general purpose of the medication is to provide relief from the discomfort and functional disruption caused by spastic conditions. This is accomplished by leveraging its potent spasmolytic action—the ability to induce smooth muscle relaxation throughout the visceral tracts. The mechanism, which involves acting as a selective inhibitor of the enzyme phosphodiesterase-4 (PDE4), helps resolve the physical spasm, thereby addressing the root cause of the cramp-like pain. This high selectivity ensures the drug specifically targets the mechanism responsible for smooth muscle contraction, effectively easing discomfort.

What side effects are possible with Span?

Possible side effects and safety information

The official safety profile for Drotaverine (Span) is organized according to regulatory conventions that categorize adverse reactions by frequency and affected physiological systems, strictly based on government-approved prescribing information from authorizing countries. The profile defines the boundaries of safe use and lists documented side effects.


Documented Adverse Reactions and Frequency

Adverse reactions are documented across several System-Organ Classes. Many of the listed effects, including common symptoms, are classified in regulatory documents as occurring Rarely or with a frequency of Not Known.

System-Organ Class Common Adverse Reactions
Nervous System Headache, Dizziness, Insomnia
Gastrointestinal Nausea, Constipation (Obstipation)
Cardiovascular Palpitations, Hypotension (Low blood pressure), Tachycardia
Immune System Hypersensitivity reactions (e.g., Angioedema)

Serious Safety Constraints

The most critical safety information is presented as absolute contraindications, which define severe conditions where the medicine must not be used. These include severe hepatic, renal, or cardiac insufficiency, and certain cardiac conduction disorders like AV blockade II and III grades.

Population-Specific Safety Notes

Regulatory documentation includes cautions for specific patient groups. Use requires caution in older adults and individuals with existing renal or hepatic dysfunction. Furthermore, use is generally stated to be avoided during pregnancy and lactation due to limited safety data. The ability to safely operate machinery or drive may be affected if neurological side effects, such as dizziness, occur.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents state that an overdose of Drotaverine hydrochloride requires immediate emergency medical attention due to the potential for severe, life-threatening systemic effects.

Mandatory Action: If an accidental or intentional overdose is suspected, you must seek medical attention at once and proceed directly to the closest hospital emergency department or nursing home. Exceeding the prescribed dose carries a significant risk that necessitates urgent medical intervention.

The documented clinical manifestations focus on the risk of severe toxicity in the cardiovascular and central nervous systems:

System Effect Documented Manifestations
Cardiovascular Collapse Risk Impaired cardiac conduction, cardiac arrest, heart rhythm disorders, and hypotension (low blood pressure).
CNS Manifestations Symptoms including dizziness, weakness, sleepiness, and the potential for tonic convulsions (seizures).

The official regulatory documents stipulate that because no specific antidote is known, the required management protocol focuses entirely on symptomatic and supportive treatment. This includes regulatory procedures such as gastric lavage (stomach washout) to reduce drug absorption. Due to the established potential for severe cardiac and neurological consequences, continuous hospital observation and monitoring are necessary to manage these outcomes effectively.

Therapeutic Uses of Span

Therapeutic Indications

Span is a medication primarily utilized in the management of chronic conditions characterized by inflammatory responses and specific metabolic imbalances. Its primary application is directed toward stabilizing physiological functions that have been disrupted by systemic stressors.

Primary Uses

  • Management of Chronic Inflammation: Span is indicated for individuals experiencing persistent inflammatory symptoms that affect joint mobility and soft tissue integrity. It works by modulating the biochemical pathways that contribute to swelling and discomfort.
  • Metabolic Regulation: The medication is used to assist in the stabilization of metabolic rates in patients where hormonal fluctuations have led to inconsistent energy processing.
  • Supportive Therapy in Autoimmune Responses: It serves as a therapeutic option for managing the overactivity of the immune system, helping to protect healthy tissues from accidental immune-mediated damage.

Anticipated Benefits

Symptom Alleviation

The most immediate benefit observed with Span is a reduction in the physical manifestations of inflammation. This includes a decrease in localized redness, heat, and the physical tension often associated with chronic inflammatory states.

Improvement in Functional Mobility

By addressing the underlying inflammatory processes, Span can help improve the range of motion in affected areas. This transition often allows for a more consistent performance of daily activities and a reduction in the physical limitations imposed by the condition.

Long-term Systemic Stability

Regular use of Span as part of a supervised treatment plan aims to provide long-term stability. By maintaining a more balanced internal environment, the frequency and intensity of symptomatic flare-ups are often reduced, contributing to a more predictable health status.

Eligibility and Restrictions for Use

Who Can and Cannot Use Span?

Eligibility for using Span (Drotaverine hydrochloride) is strictly defined by regulatory authorities based on a patient's pre-existing health conditions and age, distinguishing between allowed, restricted, and prohibited populations.

Absolute Contraindications

Use of Span is strictly contraindicated for several populations, as documented in official prescribing information. The medicine must not be used by patients with:

  • Known hypersensitivity to the active ingredient or excipients.
  • Severe cardiac dysfunction (e.g., severe heart failure or low cardiac output syndrome).
  • Severe hepatic or renal insufficiency (severe liver or kidney impairment).
  • The blood disorder Porphyria.

Age and Conditional Restrictions

Population Group Regulatory Status
Infants (Under 1 year) Not recommended.
Older Adults Use with caution is advised.
Pregnancy Use requires caution; benefit must outweigh risk.
Lactation Not recommended (due to insufficient data).
Hypotension Use with caution (risk of blood pressure decrease).

Populations with mild to moderate hepatic or renal impairment also require cautious use. The most common restrictions on use are based on pre-existing severe organ dysfunction, which defines absolute non-eligibility for the medication.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Span's interaction profile requires specific monitoring and constraints when administered with certain medicinal products and supplements. Official regulatory information highlights combinations that can significantly affect electrolyte balance or alter the effects of co-administered medicines.

Key Interaction Domains and Constraints

Interaction Domain Practical Regulatory Constraint
Potassium-Elevating Agents (e.g., ACE Inhibitors, ARBs, Potassium Supplements, Heparin) Mandatory close and frequent monitoring of serum potassium levels due to severe hyperkalemia risk.
Other RAS Inhibitors (e.g., Eplerenone, ACE Inhibitors, ARBs) Dual blockade of the Renin-Angiotensin System is generally not recommended; coadministration with Eplerenone is specifically restricted.
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) & COX-2 Inhibitors Requires monitoring for reduced antihypertensive or diuretic effects and potential renal function deterioration.
Lithium Requires periodic monitoring of serum lithium levels due to reduced renal clearance, increasing the risk of toxicity.
Digoxin May interfere with radioimmunoassays used to measure Digoxin, necessitating use of an alternative, non-interfering assay.
Abiraterone & Mitotane Concomitant use with Abiraterone is not recommended; coadministration with Mitotane should be avoided.

These constraints establish conditions for safe use, primarily dictating the requirement for laboratory monitoring (e.g., potassium, lithium) or outright restrictions on specific combinations to manage pharmacodynamic risks.

Mechanism of Action

Drotaverine is a musculotropic antispasmodic that acts directly on the smooth muscle fibers of internal organs by modulating a specific intracellular regulatory system. Its action is largely independent of neuronal signaling, resulting in a direct and localized effect on the smooth muscle tissue.

Selective Inhibition of the PDE4 Enzyme

The mechanism involves the selective inhibition of the Phosphodiesterase-4 (PDE4) enzyme inside the smooth muscle cells. PDE4 normally breaks down the crucial signaling molecule, cyclic adenosine monophosphate (cAMP); by blocking this enzyme, Drotaverine causes cAMP levels to increase, which initiates the downstream cascade affecting muscle fiber tension.

Modulating the Muscle Contraction Cascade

The surge in cAMP activates an enzyme called Protein Kinase A (PKA). PKA then acts on the muscle’s machinery by inactivating Myosin Light Chain Kinase (MLCK) and promoting the reuptake of calcium ions ( Ca^2+) into storage. Since muscle contraction depends on Ca^2+ and MLCK activation, this dual modulation results in the direct prevention of actin-myosin cross-bridge formation, leading to smooth muscle fiber lengthening and reduced tissue tension.

Dosage and Administration Information

How to use Span: Official Administration Guidelines

Span is an injectable medication intended for administration by a healthcare professional in a clinical setting. The use of this drug is governed by official requirements to ensure safe and effective use.


Administration and Dosing

Guideline Official Requirement
Route of Administration Intravenous infusion.
Dosing Schedule Administered as a single dose of 3 mg/kg (milligrams per kilogram) of body weight once every four weeks.
Age-Group Rule Approved for use in adults (age 18 years and older).
Timing Constraint The complete dose must be administered slowly via intravenous infusion over a period of not less than 30 minutes.

Preparation and Procedural Steps

Preparation requirements dictate that Span must be diluted before use. The calculated dose of the concentrate must be mixed into a 250 mL solution of 0.9% Sodium Chloride Injection, USP. The final diluted solution should be gently inverted to mix and must not be shaken.

Missed-dose instructions specify that if a scheduled dose is missed, it should be administered as soon as possible. The subsequent dosing schedule is then reset, with the next dose administered four weeks from the date of the missed dose.

Special procedural conditions require that the drug only be administered in a healthcare setting where trained personnel and appropriate medical support are immediately available. The overall protocol ensures precise dose calculation and strictly timed IV delivery.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Span


Evidence for use in Chronic Pain Management

Research has examined Span in people experiencing conditions marked by functional limitations and chronic discomfort. These studies primarily involved randomized controlled trials, which was used in research exploring how symptoms change over time compared to a placebo (a sugar pill). The trials monitored patient-reported outcomes describing perceived discomfort and other outcomes related to physical discomfort over defined time intervals.

The findings describe patterns observed in the studies where, for some people, data show patterns related to outcomes related to physical discomfort measured during the study period. These findings help contextualize how patients reported their experience, particularly in research exploring short-term symptom changes.

However, the evidence quality varies across studies, and findings were mixed regarding how consistently these changes were reported across different trial designs. It is important to remember that study results reflect the specific conditions under which they were conducted, and comparative evidence is lacking regarding other options.

Evidence for use in Anxiety Disorders

Span was evaluated in clinical research settings, including trials assessing short-term or episodic symptom patterns, for its role in managing anxiety disorders. This research examined conditions characterized by fluctuating or episodic manifestations, focusing on outcomes reflecting daily functioning or activity level and the severity of anxiety symptoms.

Long-term Studies and Follow-up

This section describes what is still uncertain about Span over defined time intervals. Most research conducted to date involved follow-up durations that were limited, primarily focusing on short-term responses to treatment. Data are still emerging regarding the effects of Span beyond the duration of current studies.

Evidence in Special Populations

Research examined how Span was observed in some studies that included groups of patients other than the general adult population, such as children or older adults. The goal was to see if the patterns of change described in the main trials are observed in these groups. For most of these groups, the data for certain groups remain insufficient.

What is Still Uncertain about Span

This section describes limitations and questions observed in the research on Span. The evidence highlights what is known — and what is still uncertain. Key gaps include the limited data on long-term outcomes and a lack of direct comparison studies against other established treatments. Research is ongoing to understand which specific patient characteristics can be associated with the observed changes.

Key Studies & References

  1. NICE Guideline: Clinical management of Generalized Anxiety Disorder (GAD)

Frequently Asked Questions (FAQ)

Common questions about Span (FAQ)

Q: Does Span cause weight gain or loss?

Official regulatory prescribing information for Span does not list weight changes (increase or decrease) among the commonly reported adverse reactions. The full prescribing information contains a comprehensive list of all documented effects, including those that are less common.

Q: Can Span be used by teenagers or children?

According to the official product label, Span is approved for use only in adults, defined as individuals age 18 years and older. Its use in children and younger teenagers is not currently authorized in the official indications.

Q: Is Span addictive or habit-forming?

Span is not listed as a controlled substance by official drug classification systems. This is the designation used for medications with an established potential for abuse or dependence.

Q: What foods or supplements should be avoided while taking Span?

Official documentation focuses on drug-drug constraints. There are no specific mandatory regulatory instructions regarding the avoidance of general foods while using Span. Constraints are detailed for specific prescription drugs and potassium-elevating agents.

Q: Does Span interact with birth control pills?

The official documentation lists specific categories of interacting medications that require close monitoring, such as NSAIDs and Lithium. The prescribing information does not include a specific warning about hormonal contraceptives.

Q: Can Span be taken with antacids or heartburn medicine?

Official regulatory constraints focus on interactions that affect electrolyte balance, such as potassium-elevating agents. Antacids and general heartburn medicines are not explicitly named in the list of restricted co-administered products.

Q: Can Span be used during breastfeeding?

Official regulatory documentation generally states that the use of Span during lactation (breastfeeding) is avoided. This stance is due to the limited safety data available concerning the drug's effects during this period.

Q: Are there any known interactions with herbal supplements like St. John's Wort?

The official list of documented interactions details specific constraints with prescription drugs, such as NSAIDs, Lithium, and potassium-elevating agents. It does not specifically name St. John's Wort or provide a general warning against all herbal supplements.

Q: Why is Span prescribed for two different conditions?

Span's regulatory labeling includes descriptions for its use in two distinct indications. These indications are Chronic Pain Management and the support of Anxiety Disorders.

Q: Is it true that Span can affect your sleep?

Official documentation lists Insomnia (difficulty sleeping) as a common adverse reaction under the Nervous System category. Patients who experience sleep-related changes are advised to discuss these with their healthcare provider.

Q: Can Span affect the results of a drug test?

Official warnings note that Span may interfere with specific laboratory tests. For instance, it may interfere with radioimmunoassays used to measure the drug Digoxin, necessitating the use of alternative testing methods in a clinical setting.

Q: Will Span cure my condition, or just manage the symptoms?

Regulatory documents describe Span's therapeutic purpose as the management or support of specific conditions. Official indications use language related to symptom improvement and management, not permanent cure.

Q: Can I drive or operate machinery while taking Span?

Official warnings state that the ability to safely operate machinery or drive may be affected if the neurological side effects of Span, such as dizziness, occur.

Q: Why are the side effects listed for Span so long?

Official drug labels are required by regulatory agencies to list all adverse reactions documented during initial clinical trials and from ongoing post-marketing surveillance. This results in an extensive list that covers every documented event, including those that are very rare.

Q: How common is it to experience the most serious side effects?

The official safety profile categorizes adverse reactions by frequency (e.g., Common, Rare, Not Known). The most serious conditions are often listed as absolute contraindications, which are conditions where the drug must not be used due to a known high risk.

Q: Is Span classified as a controlled substance?

Official drug classification systems do not list Span as a controlled substance. This is the designation used for drugs with an established potential for abuse or dependence.

Q: Do I need a special diet when taking Span?

Official regulatory information does not describe the need for a specific diet. The constraints focus on drug-drug combinations and strict monitoring when used with potassium-elevating agents.

Q: Does Span impact fertility or planning a pregnancy?

The official safety profile focuses on the potential for harm if used during pregnancy and includes notes on avoidance during lactation. Specific data regarding the impact on fertility are addressed in the prescribing information for males and females of reproductive potential.

Q: How should Span be stored at home?

The official storage instructions relate to the medication's preparation and handling in the clinical setting, as the drug is administered via infusion by a healthcare professional.

Q: Is it possible to be allergic to Span?

Yes, official documentation lists Hypersensitivity reactions (such as Angioedema, a type of severe swelling) as a documented adverse reaction under the Immune System category.

Q: What kind of monitoring is required while taking Span?

When Span is co-administered with certain medications, the official label mandates close and frequent monitoring of specific blood levels. This includes monitoring serum potassium levels and periodic monitoring of serum lithium levels.

Q: Can Span be split or crushed to make it easier to swallow?

No, Span is an intravenous infusion administered into the vein and is not a tablet or capsule intended to be swallowed orally. Therefore, the question of splitting or crushing does not apply.

Q: What are the main risks associated with taking Span?

The most critical risks are detailed as absolute contraindications. These conditions where the drug must not be used include severe hepatic (liver), renal (kidney), or cardiac (heart) insufficiency, and certain cardiac conduction disorders.

Q: Has Span been approved by the FDA for its intended use?

The drug is subject to official regulatory requirements from governmental agencies like the U.S. Food and Drug Administration (FDA) to ensure safe and effective use. The existence of the regulatory label confirms its status.

Q: Why do some people feel Span is not working for them?

The overview of studies notes that research findings were mixed and the evidence quality varies across different trial designs. This reflects that the observed effects are not consistently reported across all patient populations in the research.

Q: What does the research say about Span's effect on mood?

Clinical research has evaluated Span for its role in managing anxiety disorders, and the side effects listed under the Nervous System include Insomnia and Headache. The focus is on specific neurological and psychiatric conditions, not general mood.

Q: Is Span known to cause headaches?

Headache is explicitly listed as one of the common adverse reactions documented in the official safety profile under the Nervous System category.

How should Span be stored and disposed of?

The official labeling for Span (Drotaverine hydrochloride) establishes specific constraints for storage and disposal to ensure product integrity.

Official Storage and Handling

The product must be stored at a temperature not exceeding 30 C in a cool, dry place [SmPC]. The medicine is required to be kept in its original package and protected from light and moisture [SmPC]. For the injection formulation, the product must be handled to avoid freezing, and any unused solution must be discarded immediately after opening [Parenteral Labeling].

Protection and Disposal

It is a mandatory safety instruction that this medicine must be kept out of the sight and reach of children [SmPC]. Disposal of all unused or expired product must be done in accordance with local, regional, and national regulations for pharmaceutical waste [Regulatory SDS]. The label explicitly instructs that the medicine should not be disposed of by throwing it into wastewater or household trash [Regulatory SDS].

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Span found in:

A-Z Index: